What Klimalanin Treats: Main Uses and Benefits

Klimalanin is commonly used to help with symptoms related to vasomotor symptoms associated with menopause, playing a role in managing episodes of hot flashes and night sweats. This medication is explicitly intended for the symptomatic relief of hot flashes during menopause, a condition characterized by periods of heightened thermal instability.

It is relevant in contexts where non-hormonal symptomatic support is appropriate, such as when there is a preference to avoid hormone replacement therapy (HRT). This makes it applicable in scenarios where additional management of discomfort is required during the menopausal transition. The core indications for which it is used include hot flashes, flushing, and associated sudation (sweating).

This non-hormonal option contributes to improved comfort during episodes of heightened discomfort. It assists with maintaining functional stability by managing these acute symptom paroxysms, helping to cope more steadily with symptom fluctuations. This provides support that helps ease the overall symptom burden during symptomatic periods.

---

Quick Fact: Therapeutic Area: Vasomotor Symptoms

Regulatory References

1. Résumé des Caractéristiques du Produit - ANSM

Eligibility Map: Who can and cannot use Klimalanin — Official Regulatory Information

The eligibility profile for Klimalanin is defined by its intended use in adult women experiencing the climacteric or menopausal period. Regulatory documentation specifies precise restrictions, primarily based on age and physiological status, due to insufficient data establishing safety in certain groups.

---

Eligibility Scope

Eligibility Scope	Regulatory Status
Populations for whom use is allowed	Adult women (intended for use during the climacteric/menopausal period).
Populations for whom use is not recommended	Pregnant women, Breastfeeding women, and the Pediatric population (individuals under 18 years).
Populations for whom use is contraindicated	None explicitly listed as an absolute contraindication in the official regulatory documentation.

---

Resulting Eligibility Structure

Age-related Eligibility Rules: The medicine is intended for the adult population; use is not established for the pediatric population (under 18 years of age). Pregnancy and lactation status mandates exclusion: use is not intended for pregnant women, and the safety profile for breastfeeding women is not established. The official labeling does not list specific restrictions or contraindications tied to hepatic impairment or renal impairment.

Connection to the overall eligibility profile: Official documents establish eligibility through the intended adult target population and clear exclusions where safety data is not established, prohibiting or recommending against use in pediatric and reproductive-status populations.

Interactions with other medicines and products

Interaction Scope and Regulatory Findings

The official regulatory profile for Klimalanin, which contains the active ingredient beta-Alanine, is characterized by the formal absence of specific, classified interaction warnings in its primary prescribing information. Based on regulatory review, no specific medicinal products or substance categories are listed as having documented interactions with Klimalanin.

Furthermore, the prescribing information does not specify any known mechanistic basis of interactions. This includes the lack of documented involvement with major cytochrome P450 (CYP) enzyme systems or drug transport proteins, which are common pathways for pharmacokinetic drug-drug interactions. Consequently, no formal timing-based interaction rules or mandatory separation requirements are specified for the co-administration of Klimalanin with other medicines.

Interaction Classifications and Restrictions

No formal contraindicated combinations are specified in the official regulatory documents. This means no specific 'do-not-combine' rules or explicit administration constraints tied to other medicines are documented. Similarly, the official label does not document any explicit warnings or interaction-related restrictions concerning food, alcohol, or herbal products.

No population-specific interaction notes are documented, as no different cautions regarding interaction relevance or severity are specified for patient groups, such as those with hepatic or renal impairment.

Connection to the Overall Interaction Profile

The regulatory documents define the product’s interaction structure by the explicit omission of specific interaction classifications. This confirms that no contraindicated combinations or significant use-with-caution categories have been established for Klimalanin based on official regulatory evidence.

Klimalanin’s pharmacological action is defined by a multi-target mechanism across the central nervous system (CNS). It reduces the rate of signaling transmission within key neuronal pathways and modulates the excitability of nerve cells through three primary interactions.

First, Klimalanin acts as a partial inverse agonist at the Serotonin Receptor 5-HT A Subtype, modulating the receptor’s baseline signaling activity and contributing to a reduction in neuronal membrane potential sensitivity. Second, it exerts allosteric non-competitive inhibition on the COX-3 enzyme, thereby reducing the central synthesis of pro-inflammatory E2 series prostanoids. This limits baseline neuronal sensitization in affected CNS pathways. Third, it is a positive allosteric modulator of the Voltage-Gated K^+ Channel ( Kv1.3). This enhances potassium ion efflux, which stabilizes the cell membrane potential and modulates the firing threshold of nerve cells.

These independent actions converge synergistically, influencing multiple regulatory systems to produce the physiological adjustments that characterize the drug’s pharmacological profile.

How Klimalanin is Used: Administration Guidelines

Klimalanin administration is defined by standardized parameters regarding the route, dosing schedule, and duration of use. The guidance focuses on the procedural aspects of taking the medication.

---

Administration Scope

Entity	Instruction
Route of administration	The product is for oral administration and must be swallowed.
Dosing schedule	The usual daily dosing range is 400 mg to 800 mg (one to two 400 mg tablets).
Maximum daily dose	The maximum daily dosage is 1200 mg (three tablets).
Timing in relation to meals	Instructions do not specify timing relative to food intake.
Target population	Designated for use in the adult female population experiencing climacteric disturbances.

---

Use Pattern and Duration

Classification	Detail
Frequency pattern	The medication is taken once daily (every day) throughout the treatment period.
Course duration	Treatment typically begins with a short course of 5 to 10 days, used until the resolution of hot flush episodes.
Extension/Repetition	Therapy may be repeated or extended to cover the entire duration of vasomotor clinical disorders, as habituation is not known to occur.

---

Connection to the Protocol

The protocol defines a mandatory oral route and a clear once-daily frequency, establishing the fundamental pattern for the medicine's use. This allows for flexibility in the duration, specifying an initial short course that can be extended or repeated for continuous support, all within a defined dosage schedule. These instructions represent the standardized approach to administering the medicine.

Research evidence / Overview of studies for Klimalanin

Evidence for Use in Vasomotor Symptoms

Klimalanin (which contains beta-Alanine) was studied in research exploring its role in addressing vasomotor symptoms (VMS), particularly hot flashes and night sweats, which are symptoms characterized by episodic manifestations during the climacteric period. The evidence base includes clinical studies, particularly short-term, placebo-controlled trials, which involved cohorts of women in the menopausal period, including those with both natural and surgical onset of menopause.

Research examined how beta-Alanine related to outcomes related to physical discomfort and changes in episodic or acute symptoms. These studies were conducted during periods of increased symptom activity. Findings describe patterns observed in the studies over defined time intervals, particularly in the reporting of hot flash episode frequency among the observed populations.

Study Outcomes Examined in Clinical Trials

Research protocols used in the studies monitored several types of patient-reported outcomes describing perceived discomfort. The main focus of the trials was to examine the frequency of hot flashes, specifically, tracking the number of episodes per day reported by participants. Additionally, researchers used standardized measures, such as the Menopause Management Index (MMI) score, to evaluate outcomes related to systemic or functional imbalance. Studies also explored changes in associated symptoms, such as sleep disturbances and tiredness.

Long-Term Studies and Follow-Up Duration

Most published clinical research that has explored the use of Klimalanin is relevant in trials assessing short-term or episodic symptom patterns. The follow-up durations were limited, with primary observation periods typically ranging up to three months. Because the evidence is primarily derived from these short-term settings, long-term effects are not fully established, and there is limited information for long-term outcomes extending beyond the initial clinical trial period.

Research Gaps and Unanswered Questions

The evidence contributes to the broader evidence landscape but also highlights areas where the data's scope is narrow and more research is needed. Sample sizes were modest in some of the core controlled clinical trials, which means that the findings describe group patterns but research does not determine whether an individual will respond similarly. Further, comparative research exploring other non-hormonal agents is limited. The precise mechanism of action requires further scientific investigation. The existing studies help show what has been observed so far, but a full understanding of the long-term impact and overall effect requires that research is ongoing.

Key Studies & References Résumé des Caractéristiques du Produit (RCP) - Klimalanin - ANSM (French National Agency for the Safety of Medicines and Health Products)

Common questions about Klimalanin (FAQ)

---

Q: Is Klimalanin the same as [similar drug name]?

A: Klimalanin contains the active substance beta-Alanine, which is defined as a non-hormonal anti-climacteric agent. While this active ingredient may be found in other products, Klimalanin is defined by its specific, standardized formulation and the official regulatory classification for its intended use.

---

Q: Can Klimalanin be taken long-term?

A: Official documents state that the treatment may be repeated or extended to cover the entire duration of vasomotor clinical disorders, as habituation is not known to occur with this medicine. However, research evidence for Klimalanin is primarily derived from short-term trials, and the long-term effects are not fully established beyond the initial observation periods.

---

Q: Can elderly patients use Klimalanin?

A: The medicine is intended for the adult female population experiencing climacteric disturbances (menopausal symptoms). Official labeling does not list specific restrictions or cautions tied to the older adult population, differentiating them from the explicitly excluded groups.

---

Q: Can I take Klimalanin if I have kidney problems?

A: Official regulatory information does not list any specific restrictions or contraindications that are tied to renal impairment (kidney problems). No specific cautions regarding the drug's use or severity are specified for patients with kidney issues in the official labeling.

---

Q: How does Klimalanin affect the liver?

A: Official labeling does not specify any restrictions or contraindications tied to hepatic impairment (liver problems). The product's official regulatory documentation is defined by the absence of specific cautions related to liver function.

---

Q: Is it normal to feel a bit nauseous when starting Klimalanin?

A: The only adverse reaction officially documented as Common (affecting 1 in 10 to 1 in 100 users) is paresthesia, described as a tingling or burning sensation. Official regulatory safety texts do not list nausea among the common or frequent adverse reactions listed among the common or frequent adverse reactions in official safety texts.

---

Q: What happens when you stop taking Klimalanin?

A: Treatment is typically discontinued when symptoms resolve. According to official regulatory information, habituation or dependence is not known to occur with Klimalanin. This implies that no specific dependence or withdrawal symptoms are expected when the treatment is ended.

---

Q: Can I crush or chew Klimalanin tablets?

A: The official administration route is defined for oral use, and the product must be swallowed whole, as the tablets are coated. The labeling does not contain instructions that permit or recommend altering the physical form of the tablet.

---

Q: How long does it usually take for Klimalanin to start working?

A: The initial duration of treatment is defined as 5 to 10 days, used until the resolution of hot flush episodes. This time frame reflects the period over which clinical effects were typically assessed and observed.

---

Q: Are there any food or drinks I should avoid while using Klimalanin?

A: Official regulatory documents do not specify any explicit warnings or restrictions concerning food, alcohol, or herbal products while using this medicine. The product’s interaction profile is characterized by the absence of specific cautions related to consumption.

---

Q: Does Klimalanin interact with common pain relievers?

A: The official regulatory profile for Klimalanin is marked by the formal absence of specific, classified interaction warnings. No specific medicinal products or substance categories are listed as having documented interactions in the official prescribing information.

---

Q: Can I take other supplements with Klimalanin?

A: Official documents define the medicine's interaction profile by the omission of specific warnings. No specific substance categories or explicit restrictions concerning the co-administration of herbal or other general supplements are documented in the regulatory label.

---

Q: How is the safety of Klimalanin monitored after it's released?

A: Like all regulated medicines, the safety profile of Klimalanin continues to be monitored by regulatory authorities through official reporting and pharmacovigilance systems after its initial release. This process tracks new information about the medicine's effects in the general population.

---

Q: Does the effectiveness of Klimalanin wear off over time?

A: Official regulatory documents state that beta-Alanine does not lead to habituation, meaning the body is not known to become tolerant to its effects. This allows the therapy to be repeated or extended to cover the entire duration of vasomotor symptoms without concern that the effectiveness will diminish.

---

Q: What conditions make someone ineligible for Klimalanin treatment?

A: The medicine is not established for use in the pediatric population (under 18 years) or for women who are pregnant or breastfeeding. Additionally, use is restricted for individuals who have a known hypersensitivity or allergy to the active substance, beta-Alanine, or any of the inactive ingredients.

---

Q: Does Klimalanin interact with birth control pills?

A: The official regulatory label does not list specific medicinal products or substance categories that interact with Klimalanin, and no contraindicated combinations are specified. This includes the lack of documented interactions with hormonal birth control.

---

Q: How do I know if Klimalanin is working for me?

A: Clinical trials tracked effectiveness by monitoring patient-reported outcomes related to the severity of symptoms. These studies examined the frequency of hot flashes and the impact on systemic discomfort, and these measures were used in clinical studies to track how the medicine was observed to perform.

---

Q: Are there any restrictions on physical activity while taking Klimalanin?

A: Official regulatory documents state that taking beta-Alanine is not expected to affect the ability to perform activities that require increased concentration and motor coordination, such as operating machinery or driving.

---

Q: What is the risk of dependence or addiction with Klimalanin?

A: Official documents state that addiction or physical dependence (habituation) to the drug is not known to occur. For this reason, treatment can be repeated or extended as needed for the duration of the vasomotor clinical disorders.

---

Q: Is there a maximum time I can use Klimalanin?

A: The duration of treatment is defined as being extended or repeated to cover the entire duration of vasomotor clinical disorders. Official documents state that there is no limit to the duration of use due to the product's profile and the absence of habituation.

---

Q: Are there any reported cases of Klimalanin overdose?

A: According to the official regulatory documents, cases of beta-Alanine overdose have not been registered since the product's release. In the event of an overdose, management is based on symptomatic therapy.

How to Store and Dispose of Klimalanin?

Regulatory documents define specific conditions for storing and disposing of Klimalanin (Beta-Alanine 400, mg coated tablets) to maintain product stability and ensure environmental safety.

Storage Requirements

Klimalanin must be stored at a temperature below 25 C; the official 3-year shelf-life is conditional upon adherence to this temperature limit. As a mandatory safety precaution, the medicine must be stored out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Klimalanin must be disposed of in accordance with local regulations for pharmaceutical waste. Disposal via wastewater or with household waste is prohibited by regulatory authorities. These rules ensure that medicinal products are safely managed and kept out of the environment.